Skip to main content

Drug Interactions between Ed Cyte F and oxidronate

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ferrous fumarate oxidronate

Applies to: Ed Cyte F (ferrous fumarate/folic acid) and oxidronate

MONITOR: Administration of technetium (Tc 99m) oxidronate after chelating agents, diphosphonates, tetracyclines, or iron containing drugs may reduce the quality of the scintigraphic procedure by decreasing the accumulation of Tc 99m oxidronate in skeletal bone. The exact mechanism of the interaction is unknown; however, it may be related to the effects of the interacting drugs on bone homeostasis.

MANAGEMENT: Proceed with caution if chelating agents, diphosphonates, tetracyclines, and iron-containing drugs are used prior to technetium (Tc 99m) oxidronate. The quality of the resulting imaging may be reduced.

References (7)
  1. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  2. (2018) "Product Information. TechneScan HDP (oxidronate)." Curium Pharmaceuticals
  3. (2023) "Product Information. Technescan HDP (oxidronate)." Landauer Radiopharmaceuticals Pty Ltd
  4. (2021) "Product Information. HDP (Radpharm) (oxidronate)." Global Medical Solutions Pty Limited t/a Radpharm Scientific
  5. (2023) "Product Information. Technescan HDP Kit (oxidronate)." Curium Pharma UK Ltd
  6. Warner AJ, Hathaway-Schrader JD, Lubker R, Davies C, Novince CM (2023) Tetracyclines and bone: unclear actions with potentially lasting effects. https://www.sciencedirect.com/science/article/abs/pii/S8756328222000539
  7. Balogh E, Paragh G, Jeney V (2023) Influence of iron on bone homeostasis. https://www.mdpi.com/1424-8247/11/4/107

Drug and food interactions

Moderate

folic acid food

Applies to: Ed Cyte F (ferrous fumarate/folic acid)

MONITOR: Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics. Excessive alcohol consumption may lead to folate deficiency.

MANAGEMENT: Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.

References (5)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  4. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
  5. (2017) "Product Information. Folic Acid (folic acid)." Method Pharmaceuticals, LLC
Moderate

ferrous fumarate food

Applies to: Ed Cyte F (ferrous fumarate/folic acid)

ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.

Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

References (2)
  1. "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
  2. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer